Treatment of HIV related non-Hodgkin's lymphoma (NHL) with chemotherapy (CT) and granulocyte-colony stimulating factor (G-CSF): reduction of toxicity and of days of hospitalization with concomitant overall reduction of the cost (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Sixth International Symposium, Supportive Care in Cancer, March 2-5, 1994, New Orleans, LA. Multinational Association of Supportive Care in Cancer, Brussels, Belgium, AO-5, 1994.. Unique Identifier : AIDSLINE ICDB/95611920
Tirelli U; Vaccher E; Spina M; Errante D; Tavio M; Polizzi P; Bernardi D; Talamini R; Carbone A; Div. of Medical Oncology and AIDS, C.R.O., Italy

Abstract: The aim of this study is to compare the toxicity and the cost of CT with G-CSF vs CT without G-CSF. We have analyzed 37 consecutive patients (pts) treated with intensive CT regimens, 19 pts from July 1989 to June 1991 without G-CSF and 18 pts from July 1991 to September 1992 with G-CSF, 5 ug/kg/day sc starting 24 hr after CT for 13 days in all cycles. The CT regimens employed were the LNH 84 regimen and the CHOP-like regimen, CHVmP/VCR-BLM given for 3-6 cycles. The analysis was performed only for the first 3 cycles of CT. The cost of 1 day of hospitalization in our division is about 450 US dollars (data presented in a table). The side effects of G-CSF were uncommon and mild. We have shown that treatment with G-CSF significantly reduced the nadir WBC in pts with CD4+ greater than or equal to 200, the mean delay between the CT cycles and the mean toxicity related days of hospitalization. Therefore, by contrast with what one might expect, the cost of CT + G-CSF vs CT alone did not increase, actually it decreased. In conclusion, G-CSF in addition to CT should be preferred in the treatment of pts with HIV-related NHL. (2 Refs)

Keywords: Adolescence Adult Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Female Granulocyte Colony-Stimulating Factor/*THERAPEUTIC USE Hospitalization/*ECONOMICS Human HIV Infections/*COMPLICATIONS *Length of Stay Lymphoma, Non-Hodgkin's/COMPLICATIONS/*DRUG THERAPY/THERAPY Male Middle Age ABSTRACT

951130
M95B0942

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .